Recent IV-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: An open-label pilot study

World Journal of Gastroenterology

Volumn 13, Issue 4, 2007, Pages 579-584

  Witthoeft, Thomas ^a   Fuchs, M ^b   Ludwig, D ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Consensus interferon; Hepatitis C; Polymerase chain reaction; Sustained virological response

Indexed keywords

CODEINE; CONSENSUS INTERFERON; RIBAVIRIN; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; INTERFERON ALFACON-1; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLEEDING DISORDER; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GINGIVITIS; HEADACHE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LEUKOPENIA; MALE; MOOD DISORDER; MYALGIA; OPEN STUDY; SUICIDAL IDEATION; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; BLOOD; CLASSIFICATION; DRUG COMBINATION; GENOTYPE; HEPATITIS C VIRUS; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SUBSTANCE ABUSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33846799081     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i4.579     Document Type: Article

References (17)

1. Pestka S. The human interferon-alpha species and hybrid proteins. Semin Oncol 1997; 24: S9-4-S9-17
2. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002; 4:23-30
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury Y, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
5. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-S127
6. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16: 489-499
7. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26: 747-754
8. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231
9. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654-659
10. Pockros PJ, Reindollar R, McHutchinson J, Reddy R, Wright T, Boyd DG, Wilkes LB. The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. J Viral Hepat 2003; 10: 55-60
11. Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, Watts A, Howard R, Smith M. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005; 50: 727-732
12. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1098
13. Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, Suppressa S, Miracolo A, Paternoster C, Rizzo C, Rossini A, Benedetti P, Capanni M, Ferrara C, Costa P, Bertin T, Pantalena M, Lomonaco L, Scattolini C, Mazzella G, Giusti M, Boccia S, Milano S, Marin R, Lisa Ribero M, Tagger A. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 2003; 39: 843-849
14. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol 2003; 17: 479-482
15. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, Marschal O, Steffen M, Manns NW, Wedemeyer H. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44: 291-301
16. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527
17. Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 2006; 26: 319-325